September 05, 2025

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir / Madam,

Sub: Completion of US FDA Inspection at Unit-XII of Aurobindo Pharma Limited – Reg.,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is to inform you that –

The United States Food and Drug Administration (US FDA) inspected Aurobindo Pharma's Unit-XII, which includes both oral solids and injectable manufacturing unit, situated at Bachupally, Medchal Malkajgiri District, 500090, Telangana from August 25 to September 05, 2025.

At the end of the current inspection, a 'Form 483' was issued with a total of 8 observations for both (oral solids & injectable). All observations are procedural in nature. We will respond to the US FDA within the stipulated timelines.

The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.

We will keep the stock exchanges informed if there is any further information relating to the above in the future.

The details of action initiated by US FDA in the prescribed format as required under Regulation 30 of the SEBI Listing Regulations are enclosed as Annexure.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

Digitally signed by BADDIGAM ADI REDDY
Date: 2025.09.05 18:32:06 +05'30'

B. Adi Reddy
Company Secretary

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

S.No	Particulars	Details
1.	Name of the authority	U.S. Food and Drug Administration (US FDA), USA
2.	Nature and details of the action(s) taken, initiated or order(s) passed by the Authority	The United States Food and Drug Administration (US FDA) inspected Aurobindo Pharma's Unit-XII, which includes both oral solids and injectable manufacturing unit, situated at Bachupally, Medchal Malkajgiri District, 500090, Telangana from August 25 to September 05, 2025. At the end of the current inspection, a 'Form 483' was issued with a total of 8 observations for both (oral solids & injectable). All observations are procedural in nature. We will respond to the US FDA within the stipulated timelines.
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	September 05, 2025
4.	Details of the violation(s)/ contravention(s) committed or alleged to be committed	At the end of the current inspection, a 'Form 483' was issued with a total of 8 observations for both (oral solids & injectable). All observations are procedural in nature. We will respond to the US FDA within the stipulated timelines.
5.	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no impact on the Company's financials or operations due to the said action.

Digitally signed by BADDIGAM ADI REDDY
Date: 2025.09.05 18:32:33 +05'30'